Intravenous alpha1-antitrypsin in a child with deficiency and severe lung disease.

REFERENCES 1 Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177: 108–113. 2 Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212–1217. 3 Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38: 1178–1185. 4 Sitbon O. HIV-related pulmonary hypertension: clinical presentation and management. AIDS 2008; 22: Suppl. 3, S55–S62. 5 Feiterna-Sperling C, Huseman D, Timme J, et al. Resolution of human immunodeficiency virus type 1 infection-related severe pulmonary hypertension in a very low-birth-weight infant. Pediatr Infect Dis J 2008; 27: 564–567. 6 Speich R, Jenni R, Opravil M, et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001; 131: 663–665. 7 Pellicelli AM, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001; 52: 31–41. 8 Pellicelli AM, D’Ambrosio C, Vizza CD, et al. HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. Acta Cardiol 2004; 59: 323–330. 9 Barbaro G, Lucchini A, Pellicelli AM, et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92: 1164–1166. 10 Torre D, Pugliese A. Impact of antiretroviral therapy among HIV-1-infected patients with pulmonary hypertension. Clin Infect Dis 2004; 39: 1549–1550.